S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
NASDAQ:ALZN

Alzamend Neuro - ALZN Stock Forecast, Price & News

$1.16
+0.01 (+0.87%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.14
$1.19
50-Day Range
$1.02
$1.48
52-Week Range
$0.80
$3.16
Volume
70,913 shs
Average Volume
318,446 shs
Market Capitalization
$110.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Alzamend Neuro MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
7.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Alzamend Neuro in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$38,040 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

1038th out of 1,047 stocks

Pharmaceutical Preparations Industry

506th out of 512 stocks

ALZN stock logo

About Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

ALZN Stock News Headlines

YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
Friday 4/29 Insider Buying Report: ALZN, BX
See More Headlines
Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

ALZN Company Calendar

Last Earnings
12/12/2021
Today
12/02/2022
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALZN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-12,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.15 per share

Miscellaneous

Free Float
N/A
Market Cap
$110.76 million
Optionable
Not Optionable
Beta
-0.65

Key Executives

  • Mr. Stephan Jackman (Age 46)
    CEO & Director
    Comp: $473.12k
  • Mr. Kenneth S. Cragun CPA (Age 61)
    Sr. VP of Fin.
  • Mr. David J. Katzoff (Age 60)
    Chief Financial Officer
  • Mr. Henry C. W. Nisser Esq. (Age 53)
    Exec. VP, Gen. Counsel & Director













ALZN Stock - Frequently Asked Questions

How have ALZN shares performed in 2022?

Alzamend Neuro's stock was trading at $1.90 at the start of the year. Since then, ALZN stock has decreased by 38.9% and is now trading at $1.16.
View the best growth stocks for 2022 here
.

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,140,000 shares, an increase of 27.4% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 530,300 shares, the days-to-cover ratio is currently 4.0 days. Approximately 7.3% of the shares of the company are short sold.
View Alzamend Neuro's Short Interest
.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its earnings results on Sunday, December, 12th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02.

When did Alzamend Neuro IPO?

(ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.

What is Alzamend Neuro's stock symbol?

Alzamend Neuro trades on the NASDAQ under the ticker symbol "ALZN."

Who are Alzamend Neuro's major shareholders?

Alzamend Neuro's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.29%), BlackRock Inc. (0.62%) and Group One Trading L.P. (0.00%). Insiders that own company stock include David J Katzoff, L Mary Smith, Mark Gustafson, Milton C Ault III, Milton C Ault III, Milton C Ault III and Stephan Jackman.
View institutional ownership trends
.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alzamend Neuro's stock price today?

One share of ALZN stock can currently be purchased for approximately $1.16.

How much money does Alzamend Neuro make?

Alzamend Neuro (NASDAQ:ALZN) has a market capitalization of $110.76 million.

How can I contact Alzamend Neuro?

The official website for the company is www.alzamend.com. The company can be reached via phone at 844-722-6333.

This page (NASDAQ:ALZN) was last updated on 12/2/2022 by MarketBeat.com Staff